Investors

Overview

Corporate Profile

Forward Pharma is a NASDAQ traded Danish biopharmaceutical company that since 2005 has been developing FP187, a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications. The Company owns a significant intellectual property (IP) portfolio related to DMF formulations. We granted to Biogen an irrevocable license to all of our IP through the recent Settlement and License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion on February 9, 2017. We have opportunities to receive royalties from Biogen on sales of Tecfidera® or other DMF products for MS, dependent on, among other things, the U.S. interference outcome, Hart-Scott-Rodino (HSR) antitrust clearance and the ‘355 opposition outcome in Europe.

Forward Pharma A/S was founded in 2005 and is headquartered in Copenhagen, Denmark, in the heart of Medicon Valley. Since 2007 we have also operated out of a subsidiary, Forward Pharma GmbH, in Leipzig, Germany, and since August 2014 out of a subsidiary in the United States, Forward Pharma USA, LLC.


Most Recent Presentation
Download Documentation Credit Suisse Healthcare Conference

Stock Information
FWP (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Financial Status IndicatorC
Price$19.50
Change (%) Stock is Down 0.31 (1.56%)
Volume18,480
Data as of 04/21/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock chart for: FWP.OQ.  Currently trading at $19.50 with a 52 week high of $32.70 and a 52 week low of $14.89.

Recent NewsMore >>
DateTitle 
04/18/17Forward Pharma Reports Fourth Quarter and Year End 2016 Financial and Operational Results
COPENHAGEN, Denmark, April 18, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward” or the “Company”), today reported financial results for the fourth quarter and year ended December 31, 2016. Net income for the fourth quarter December 31, 2016 was $9.6 million while net loss for the year ended December 31, 2016 was $33.3 million, or $0.20 and $(0.71) per diluted share, respectively. On a non-GAAP basis, after removing the effect of non-cash income and expense items, our... 
Printer Friendly Version
03/31/17Forward Pharma Intends to Appeal Decision in Patent Interference Proceeding with Biogen Inc.
COPENHAGEN, Denmark, March 31, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (FWP) (“Forward Pharma” or the “Company”), a biopharmaceutical company that commenced development in 2005 of FP187, a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that it intends to file an appeal challenging today’s decision by the Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office (“USPTO”) in Pat... 
Printer Friendly Version
03/01/17Forward Pharma Appoints Claus Bo Svendsen as Chief Executive Officer and Plans to Reorganize to Reduce Burn Rate Following the Settlement and License Agreement with Biogen
COPENHAGEN, Denmark, March 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or the “Company”) today announced that its Board of Directors has appointed Claus Bo Svendsen, M.D., Ph.D. as Chief Executive Officer, effective March 1, 2017. He previously held the position of Executive Vice President at the Company. Dr. Svendsen succeeds Peder M. Andersen, M.D., who has led the Company since 2012. Dr. Andersen will retain his role as Chief Operating Officer and serve until Septe... 
Printer Friendly Version
02/09/17Forward Pharma Received US$ 1.25bn pursuant to Settlement and License Agreement with Biogen
COPENHAGEN, Denmark, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”) today announced that it has received a non-refundable cash fee of US$ 1.25 billion in connection with the execution and delivery of a Settlement and License Agreement with two wholly owned subsidiaries of Biogen Inc. and certain other parties (the “License Agreement”). On January 17, 2017 Forward entered into the License Agreement subject to the approval of its shareholders and certain... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
05/03/17
through
05/04/17
Forward Pharma A/S at Deutsche Bank 42nd Annual Health Care Conference
06/06/17
through
06/09/17
Forward Pharma A/S at Jefferies 2017 Global Healthcare Conference
LocationNew York, NY
06/20/17
Forward Pharma A/S at JMP Securities Life Sciences Conference
LocationNew York, NY
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Forward Pharma A/S posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources